

R H I N O M E D

RHINOMED to present at 4th Annual Microcap Investment Summit

Melbourne, Monday 14 October 2013

Consegna Group Limited (ASX:CGP), to be renamed Rhinomed Limited subject to shareholder approval, will be presenting at the 4th Annual Australian Microcap Investment Conference on 23rd October in Melbourne.

“The Microcap investment conference provides us with ideal opportunity to brief the investment community on our progress as we lead up to the launch of the Turbine”, said CEO Michael Johnson. “The company has now reached an exciting new phase. We have commenced manufacturing and our website is live. We are inviting everyone to register on the site to be among the first to have their opportunity to pre-order the Turbine prior to the launch in November.”

In addition to the presentation, a one-page investment summary will be provided to all attendees at the conference and is attached to this announcement.

Michael Johnson
Chief Executive Officer

Media Enquiries

Michael Johnson, CEO & Executive Director
+61 (03) 9614 3663
mjohnson@rhinomed.com.au

About Rhinomed Limited (ASX:CGP)

Consegna (soon to be named Rhinomed Limited subject to shareholder approval at the forthcoming AGM) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise application of its BreatheAssist technology portfolio in the Sport, Snoring, Olfactory, Sleep and Drug Delivery markets. It is launching its first Product the **Turbine™** nasal dilator later this year. For more information go to www.rhinomed.com.au.

About the Turbine™

The **Turbine™** is a revolutionary product, which utilises the BreatheAssist technology and can deliver to athletes on average 38% increase in airflow through the nasal passages. The **Turbine™** product range has been designed for both professional and amateur athletes participating in sports and fitness activities ranging from triathlon, cycling, running and non-impact sports to elite training environments, such as altitude training.

CONSEGNA GROUP LIMITED*
ABN 12 107 903 159
WWW.RHINOMED.COM.AU

SUITE 1, 1233 HIGH STREET, ARMADALE VICV 3143
TEL: +61 (0) 9824 5254
FAX: +61 (0) 9822 7735

*name changing to RHINOMED LIMITED subject to shareholder approval

RHINOMED

(ASX:CGP)

The future of nasal medical technology

COMPANY OVERVIEW

'Make every breath count'

- Change from Consegna to Rhinomed subject to shareholder approval;
- Rhinomed is a nasal and respiratory technology company that seeks to dramatically improve breathing, and the efficiency and function of the nose;
- Streamlined operations and a clear strategy for commercialisation of nasal and respiratory products;
- Rhinomed's first product, the Turbine™ nasal dilator, will be launched into the sports market in late 2013 marking the start of revenues for the company;
- Prioritising the sports market is a commercially driven decision that will enhance Rhinomed's capacity to further invest in the development of its products for other markets: sleep/snoring and sleep apnea; wellbeing (weight management, yoga/pilates); and clinical (drug delivery for allergies, migraine) from 2014;
- Under the leadership of Executive Director, Michael Johnson, Rhinomed is building a team with a strong marketing and commercialisation background, which is critical to the commercial success of its technology portfolio.

PRODUCT PORTFOLIO

ON MARKET - CONSUMER LAUNCH Q2 FY14

SPORTS - Turbine™

- » Turbine design complete and market ready;
- » Manufacturing partner secured;
- » Strong athlete endorsement & elite user trial;
- » Core target: males 20-50 years old across cycling, running, triathlons and aerobic sports initially;
- » A sophisticated international sports brand being built.

IN DEVELOPMENT - ROLLOUT 2014 & BEYOND

SLEEP - snoring & obstructive sleep apnea

- » Clear unmet needs;
- » Target males > 40 years plus;
- » Product design in progress for snoring & early stage sleep apnea;
- » Anticipated launch 2014.

WELLBEING - nasal congestion, appetite suppressant, yoga/pilates

- » Fragrance trial 2014;
- » Yoga & pilates product roll out in 2014.

DRUG DELIVERY - nasal medical delivery

- » Avoids current drug delivery issues;
- » Rapid uptake into blood stream;
- » Potential for patent extensions;
- » Potential treatment for sinus diseases and allergies;
- » First trial programme being defined - migraine.

IP & TECHNOLOGY

- A nasal dilator with ability to adjust the dilation on each side;
- Comfortable and discrete to wear;
- Made of medical grade polymer;
- Nasal breathing facilitates parasympathetic nervous system (reduces anxiety, slows heart rate and reduces muscle tension);
- 18 patents granted & pending in major jurisdictions;
- Trademarks granted & pending;
- Global manufacturing partner secured for development in all areas.

TRIAL RESULTS

- Clinical trial at the Royal Eye & Ear Hospital concluded that 38% increase in air intake;
- Elite athlete user trial:
 - » 86% believed delivered more air to lungs;
 - » 60% felt less fatigued;
 - » Elite athlete trial - in professional sports clubs in pre-season 2014.

UPCOMING MILESTONES

Clear milestones for next 6 months:

- Deliver revenues with launch of sports product; the 'Turbine', November 2013;
- Product development in snoring and well-being set for 2014 launch;
- Clinical program: sleep apnea & drug delivery commence in 2014.

AT A GLANCE

ASX:CGP

Name change from Consegna to Rhinomed to reflect focus on nasal technology.

(NOTE: RNO will be the new ASX code after ratification of name change at the AGM)

Share Price	AUD\$0.039 (01/10/2013)
Market cap	\$13 million (01/10/2013)
Cash Position	\$1.537 million (01/10/2013)
Issued Capital	331,252,461 (01/10/2013)

TOP 5 SHAREHOLDERS

1.	National Nominees	5.83%
2.	Prof Payment Svcs	2.59%
3.	MHBIAT Pty Ltd	2.26%
4.	HSBC Custody Nom	2.11%
5.	Celtic Cap Pty Ltd	2.09%

BOARD & MANAGEMENT

Martin Rogers - Non-executive Chairman
 Michael Johnson - Executive Director
 Lord Simon Reading - Non-executive Director
 Jane Ballantyne - Chief Marketing Officer
 Phillip Hains - Chief Financial Officer
 and Joint Company Secretary

CONTACT DETAILS

Michael Johnson - CEO

t: +61 (0) 3 9614 3663
 m: +61 (0) 417 395 550
 e: mjohnson@rhinomed.com.au

Suite 1, 1233 High Street, Armadale
 Victoria, Australia 3143